CGEN and CW9 Related Headlines
Go Back- Compugen Reports Fourth Quarter and Full Year 2025 Results
- Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
- Compugen appoints Michele Holcomb to board of directors
- Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
- Compugen monetizes royalties to AstraZeneca for up to $90 million
- Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
- Compugen to Participate in Stifel 2025 Healthcare Conference
- Compugen to present COM701 ovarian cancer data at ESMO 2025
- Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
- Compugen to Present at SITC 2025
- Compugen to Present Research at the Single Cell Genomics 2025 Conference
- Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Compugen Reports Second Quarter 2025 Results
- Compugen to present COM701 ovarian cancer trial data at ESMO conference
- Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
- Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025
- Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer
- Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
CGEN and CW9 Related Press Releases
Go Back- Compugen Reports Fourth Quarter and Full Year 2025 Results
- Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
- Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
- Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
- Compugen to Participate in Stifel 2025 Healthcare Conference
- Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
- Compugen to Present at SITC 2025
- Compugen to Present Research at the Single Cell Genomics 2025 Conference
- Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Compugen Reports Second Quarter 2025 Results
- Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
- Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025
- Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer
- Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
